A&J Science, an innovative biotech company based in South Korea and dedicated to addressing AMR, is advancing two distinct pre-clinical candidates for C. difficile infection (CDI) and non-tuberculous mycobacterial pulmonary disease (NTM-PD) indications into IND-enabling studies. These ongoing developments were recognized with the prestigious €2.9 million Eurostars-3 grant through Horizon Europe Eureka Program. This non-dilutive funding will support the preparation of a robust scientific package in collaboration with three European partners in Switzerland, Sweden, and France, and helping to advance the program towards phase 1/2 clinical trials.

In addition, A&J Science has recently been awarded a $100,000 grant from the Korean Ministry of SMEs and Startups to conduct lead optimization studies for new agents targeting methicillin-resistant S. aureus (MRSA).

As part of its growth strategy, A&J Science is expanding its geographic footprints to the U.S. and Canada, forging exciting new partnerships with renowned researchers, clinicians and institutions. The company is now preparing for a fundraising round to advance multiple pre-clinical assets into Phase 1 trials.

“Our science, together with strong global partnerships and a commitment to fighting global antimicrobial resistance challenge, ensures that A&J Science is well on its way to address medical unmet needs in this critically important field”, said CEO Hee-Jong (Jason) Hwang.

A post by A&J Science

Just like A&J Science, INCATE encourages all our ventures to share their exciting opportunities, connections, and milestones. We’d love to hear from you!
Reach out to us at comms@incate.net  and let us know what you’ve been up to.